S
Sandrine Bernhard
Researcher at Hoffmann-La Roche
Publications - 5
Citations - 475
Sandrine Bernhard is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Atezolizumab & Carboplatin. The author has an hindex of 1, co-authored 1 publications receiving 181 citations.
Papers
More filters
Journal ArticleDOI
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
Matthew D. Galsky,Jose Angel Arranz Arija,Aristotelis Bamias,Ian D. Davis,Maria De Santis,Eiji Kikuchi,Xavier Garcia-del-Muro,Ugo De Giorgi,Marina Mencinger,Kouji Izumi,Stefano Panni,Mahmut Gumus,Mustafa Ozguroglu,Arash Rezazadeh Kalebasty,Se Hoon Park,Boris Alekseev,Fabio A.B. Schutz,Jian Ri Li,Dingwei Ye,Nicholas J. Vogelzang,Sandrine Bernhard,Darren Tayama,Sanjeev Mariathasan,Almut Mecke,Ann Christine Thastrom,Enrique Grande +25 more
TL;DR: The results of IMvigor130 support the use of atezolizumab plus platinum-based chemotherapy as a potential first-line treatment option for metastatic urothelial carcinoma and the safety profile of the combination was consistent with that observed with the individual agents.
Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem for first-line (1L) treatment (tx) of locally advanced or metastatic urothelial carcinoma (mUC): Final OS from the randomized Phase 3 IMvigor130 study.
Matthew D. Galsky,Jose Angel Arranz Arija,Maria De Santis,Ian D. Davis,Aristotelis Bamias,Eiji Kikuchi,X. Garcia del Muro,Se Hoon Park,Ugo De Giorgi,Boris Alekseev,Marina Mencinger,Kouji Izumi,Javier Puente,Jian-Ri Li,Peter H. O'Donnell,Sandrine Bernhard,Chooi Lee,Fabiola Bene-Tchaleu,Sanjeev Mariathasan,Enrique Grande +19 more
TL;DR: The IMvigor130 primary analysis demonstrated statistically significant PFS benefit with 1L atezo + plt/gem (Arm A) vs placebo + PLT/Gem (Arm C) in pts with mUC as discussed by the authors .
Final overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy (chemo) in untreated locally advanced or metastatic urothelial carcinoma (mUC) from the Phase 3 IMvigor130 study.
Aristotelis Bamias,Ian D. Davis,Matthew D. Galsky,Jose Angel Arranz Arija,Eiji Kikuchi,Enrique Grande,X. Garcia del Muro,Se Hoon Park,Ugo De Giorgi,Boris Alekseev,Marina Mencinger,Kouji Izumi,Javier Puente,Jian-Ri Li,Fabiola Bene-Tchaleu,Sanjeev Mariathasan,Chooi Lee,Sandrine Bernhard,Maria De Santis +18 more
TL;DR: The authors reported a non-statistically significant OS benefit with atezo monotherapy (Arm B) vs placebo + platinum (investigator [INV] choice of carboplatin or cisplatin [carbo or cis])/gemcitabine (plt/gem; Arm C) in patients with PD-L1-high (IC2/3) mUC.
Journal ArticleDOI
1735O PD-L1 expression on immune cells by SP142 co-localises with dendritic cells and is associated with improved overall survival (OS) with atezolizumab in patients with untreated metastatic urothelial cancer (mUC)
Enrique Grande Pulido,Matthew D. Galsky,Roos Van Elzen,Romain Banchereau,Maureen Peterson,C. Sedano,Hartmut Koeppen,H. Li,Aristotle Bamias,Jose Angel Arranz Arija,Eigo Kikuchi,Maria De Santis,Ian D. Davis,Ira Mellman,S. Oh,P. Williams,Sandrine Bernhard,C.P. Lee,Maaike Kockx,Sanjeev Mariathasan +19 more
TL;DR: In this paper , the authors probed the clinical and immunologic basis underlying the trend toward favorable OS with atezolizumab alone (atezo; anti-PD-L1; Arm B) vs placebo + platinum/gemcitabine chemotherapy (chemo; Arm C) in patients (pts) with high PD-L 1 by SP142 in the Ph 3 IMvigor130 trial.
Journal ArticleDOI
Overall survival (OS) by response to first-line (1L) induction treatment with atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with metastatic urothelial carcinoma (mUC): Updated data from the IMvigor130 OS final analysis.
Enrique Grande,Aristotelis Bamias,Matthew D. Galsky,Eiji Kikuchi,Ian D. Davis,Jose Angel Arranz,Arash Rezazadeh,X. Garcia del Muro,Se Hoon Park,Ugo De Giorgi,Boris Alekseev,Marina Mencinger,Kouji Izumi,Javier Puente,Jian-Ri Li,Chooi Lee,Sandrine Bernhard,Alan Nicholas,Maria De Santis +18 more
TL;DR: The IMvigor130 trial as mentioned in this paper evaluated post-induction (Wk 18) OS in pts who completed 4 to 6 cycles of chemo followed by ≥1 dose of atezo or placebo and who had a best response of at least stable disease (SD) without PD at any time (up to and including Wk 18 tumor assessment).